Toronto, ON - March 28, 2013 - Theralase Technologies Inc. (TLT.V) ("Theralase") announced today that it has made application to the TSX Venture Exchange for approval to extend the expiry date of its outstanding common share purchase warrants.
Theralase has applied to have the expiry date of the warrants amended from April 13, 2013 to April 13, 2017 for the 1,500,000 total warrants issued on April 13, 2012. The exercise price of the warrants remains unchanged at $0.38 per warrant, with the exception that the warrants will be cancelled if they are not exercised within thirty (30) days from written notice that the closing price of Theralase's common shares had been $0.75 or greater for 10 consecutive trading days.
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing proprietary Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase's proprietary and patented laser technology.
For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
President & CEO
416-699-LASE (5273) ext. 225
Chief Financial Officer
416-699-LASE (5273) ext. 224
Director of Investor Relations
416-699-LASE (5273) ext. 258